ロード中...
Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer
BACKGROUND: The estrogen receptor (ER) inhibitor tamoxifen reduces breast cancer mortality by 31 % and has served as the standard treatment for ER-positive breast cancers for decades. However, 50 % of advanced ER-positive cancers display de novo resistance to tamoxifen, and acquired resistance evolv...
保存先:
| 出版年: | BMC Cancer |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4932681/ https://ncbi.nlm.nih.gov/pubmed/27378269 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2452-5 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|